New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
16:28 EDTBBRY, KING, RH, PCG, CLVS, BIIBOn The Fly: Closing Wrap
Stocks on Wall Street were higher, but closed well off their best levels, as the averages traded in a now-familiar pattern of a higher open followed by afternoon weakness. With just one trading day remaining in March, the Dow and S&P 500 are roughly flat for the month, while the Nasdaq has declined more than 3%. ECONOMIC EVENTS: In the U.S., personal income and consumer spending both rose 0.3% in February, matching expectations. The core PCE price index rose 0.1% in the month, which was also in-line with estimates. The final University of Michigan consumer sentiment reading for March came in at 80.0, which was down from February's 81.6 reading and a bit below expectations. In Europe, an index of executive and consumer sentiment rose to 102.4 in March from 101.2 in February, beating the consensus estimate of economists. COMPANY NEWS: BlackBerry (BBRY) reported a fourth quarter loss that was narrower than expected on revenue that missed expectations and fell below $1B for the first time since 2007. The handset maker said it sold 3.4M smartphones during the quarter. BlackBerry also said its cash and equivalents totaled $2.7B at March 1, down from $3.2B at the end of the prior quarter, and the company said it is targeting break-even cash flow by the end of its fiscal 2015. Shares of the company initially traded higher following the report, but closed down 64c, or 7.07%, to $8.41... King Digital (KING) lost another 41c, or 2.22%, to $18.08 to finish its first abbreviated week of trade down more than 14% following the "Candy Crush" maker's Wednesday initial public offering. MAJOR MOVERS: Among the notable gainers was home furnishing retailer Restoration Hardware (RH), up $8.12, or 12.73%, to $71.93 after its first quarter profit view beat estimates. Also higher were shares of Idera Pharmaceuticals (IDRA), up 69c, or 17.78%, to $4.57 after the company's Phase 2 trial of its treatment for moderate-to-severe plaque psoriasis met its primary objective. Among the noteworthy losers was PG&E Corporation (PCG), down $1.75, or 4.01%, to $41.89 after reporting that they expect that the federal government will bring criminal charges against the utility in connection with the 2010 San Bruno natural gas transmission pipeline accident. Following the announcement the stock was downgraded at Deutsche Bank and Citigroup. Also lower were a number of biotech names, including Clovis Oncology (CLVS), down $9.99, or 12.44%, to $70.33, and Biogen (BIIB), down $15.94, or 5.05%, to $294.12 as the sector continued to see significant weakness, as it often has in recent trade. INDEXES: The Dow was up 58.83, or 0.36%, to 16,323.06; the S&P 500 was up 8.58, or 0.46%, to 1,857.62; the Nasdaq was up 4.53, or 0.11%, to 4,155.76.
News For BBRY;KING;RH;PCG;CLVS;BIIB From The Last 14 Days
Check below for free stories on BBRY;KING;RH;PCG;CLVS;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 11, 2014
09:00 EDTBBRYBlackBerry acquires Movirtu, terms not disclosed
Subscribe for More Information
08:11 EDTBBRYBlackBerry October volatility elevated into Q2 and outlook
Subscribe for More Information
07:47 EDTRHRestoration Hardware bullish thesis remains intact, says RW Baird
Baird said its bullish thesis on Restoration Hardware remains intact despite the company's Q2 revenue shortfall. The firm cited stronger margins, late quarter revenue momentum, new product introductions, and expectations for margin expansion. Shares of Restoration Hardware are Outperform rated with a $90 price target.
07:31 EDTBIIBBiogen announces 5-year results from TECFIDERA ENDORSE Phase 3 study
Subscribe for More Information
07:31 EDTBIIBBiogen announces new data from Plegridy Phase 3 ADVANCE trial
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY were maintained in people with relapsing forms of multiple sclerosis beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston. Post-hoc analyses from the two-year, Phase 3 ADVANCE clinical trial confirm that PLEGRIDY’s positive effects on reducing disease activity and disability progression were maintained in year two of the study. A significantly higher proportion of patients taking PLEGRIDY during both years of the study experienced no evidence of disease activity – defined as the absence of clinical and MRI disease activity over two years of treatment – compared to those who switched to PLEGRIDY from placebo. Also, those treated with PLEGRIDY for both years of the study had significant reductions in the risk of 24-week confirmed disability progression compared to patients treated with placebo during the first year. In addition, new data from the second year of ADVANCE show that patients who took PLEGRIDY throughout the study experienced statistically significant improvements in clinical and MRI outcomes – including annualized relapse rate, risk of relapse, risk of 24-week confirmed disability progression, and number of brain lesions – when compared to those who switched to PLEGRIDY after taking placebo for the first year. This new data also showed that the safety profile of PLEGRIDY was consistent between years one and two of the study.
06:39 EDTRHRestoration Hardware shares will bounce back today, says Jefferies
Subscribe for More Information
05:57 EDTRHStocks with implied volatility above IV index mean; AMD RH
Subscribe for More Information
September 10, 2014
18:33 EDTRHOn The Fly: After Hours Movers
Subscribe for More Information
16:22 EDTRHRestoration Hardware slips lower after results, levels to watch
Subscribe for More Information
16:14 EDTRHRestoration Hardware down 2.7% after reporting Q2 results, guidance
Subscribe for More Information
16:09 EDTRHRestoration Hardware sees FY14 adjusted EPS $2.29-$2.33, consensus $2.31
Subscribe for More Information
16:08 EDTRHRestoration Hardware sees Q3 adjusted EPS 46c-48c, consensus 43c
Subscribe for More Information
16:07 EDTRHRestoration Hardware reports Q2 adjusted EPS 67c, consensus 64c
Subscribe for More Information
16:03 EDTCLVSClovis announces first patient enrolled in lucitanib Phase 2 study
Subscribe for More Information
15:50 EDTRHNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Restoration Hardware (RH), consensus 64c; Men's Wearhouse (MW), consensus $1.06; Five Below (FIVE), consensus 14c; Sigma Designs (SIGM), consensus (8c); Wet Seal (WTSL), consensus (9c).
07:22 EDTRHRestoration Hardware September volatility elevated into Q2 and outlook
Subscribe for More Information
06:00 EDTBBRYStocks with implied volatility top IV index mean; BBRY YHOO
Subscribe for More Information
September 9, 2014
08:37 EDTRHRestoration Hardware set-up favorable into earnings, says Jefferies
Jefferies views the set-up for shares of Restoration Hardware as favorable into the company's Q2 results Wednesday night. The firm believes Restoration can top the high-end of sales guidance and that concerns around product margin are overblown. Jefferies notes that as of mid-August, the short interest in the name was 21% of the float at 7.4M shares. It believes shorting the stock into the earnings announcement would be "unwise" and keeps a Buy rating on Restoration Hardware with an $88 price target.
September 8, 2014
09:27 EDTBIIBLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
07:15 EDTBIIBIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use